“We believe continuous flow manufacturing… represents the future of pharmaceutical production,” said Dr Hao Hong, Chair & CEO of Asymchem
Global CDMO Asymchem Laboratories has announced an agreement to acquire Snapdragon Chemistry, a US-based chemical technology company which specialises in continuous manufacturing and early-stage chemical process development services. The acquisition will expand Asymchem’s footprint in the US, offering customers a seamless path from preclinical process R&D through commercial cGMP manufacture.
In 2020, Asymchem made a strategic investment to help expand the company its cGMP drug substance manufacturing suites. The acquisition is hoped to further streamline the transition of client projects from early to late-stage manufacturing and commercialisation.
“We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits.” said Dr Hao Hong, Chair & CEO of Asymchem Group.
“Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool.”
“We are thrilled to be joining Asymchem, a company that shares our passion for advancing chemical manufacturing technology,” said Snapdragon President and CEO, Dr Matthew Bio. “Asymchem truly understands that commitment and we look forward to continuing to develop the high-quality solutions we are known for in their integrated service ecosystem.”
Snapdragon will operate as a standalone division, continuing its ongoing lab and manufacturing facility expansion and maintaining its current leadership team. The deal is expected to close in the second quarter of 2022.